A Multicentre, Open-label, Randomized, 6-week, Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared With Clopidogrel With Aspirin as Background Therapy in Chinese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS)

Trial Profile

A Multicentre, Open-label, Randomized, 6-week, Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared With Clopidogrel With Aspirin as Background Therapy in Chinese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS)

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Mar 2015

At a glance

  • Drugs Ticagrelor (Primary) ; Clopidogrel
  • Indications Acute coronary syndromes; Embolism and thrombosis
  • Focus Pharmacodynamics
  • Acronyms HouYi
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 Mar 2015 The primary endpoint was changed as per the statistical analysis plan prior to database lock.
    • 26 Feb 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 14 Jan 2014 Planned number of patients changed from 80 to 60, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top